Latest revenue
$258.3K
as of 2025-09-30
Latest net income
$48.6K
as of 2025-09-30
Net margin
18.8%
as of 2025-09-30
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $6.6M
- Enterprise value
- $6.6M
- P/E (trailing)
- 42.2×
- Forward P/E
- —
- P/B
- —
- Dividend yield
- 0.0%
- 52-wk high
- $0.24
- 52-wk low
- $0.00
- Beta
- —
- Shares out
- 74.6M
5-year trend
What this company does
Business. Our Company Hong Yuan Holding Group (“We”, “the Company”, “Hong Yuan”, Us” or “Our”) was incorporated on September 29, 2001, in the State of Nevada under the name of Biocorp North America Inc. On March 18, 2005, we filed an amendment to our certificate of incorporation to change our name to Cereplast, The Company is a development-stage enterprise devoting substantial efforts to establishing a new business, financial planning, raising capital, and researching products that may become part of the Company’s product portfolio. The Company has not realized significant sales since inception. A development stage company is defined as one in which all efforts are devoted substantially to…
AI summary unavailable — showing raw filing excerpt
Generated from HGYN's filing dated 2026-05-08
Key risks
Risk Factors This item is inapplicable because we are a “smaller reporting company” as defined in Exchange Act Rule 12b-2.
AI summary unavailable — showing raw filing excerpt
Generated from HGYN's filing dated 2026-05-08
Profitability
Gross margin
64.4%
70.3%Operating margin
21.1%
153.7%Net margin
18.5%
146.1%Return on equity
-247.6%
679.7%Return on assets
25.4%
157.2%Leverage
Debt / equity
-10.74×
447.6%Debt / assets
110.3%
45.9%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q4 2025 2025-12-31 | $225.5K | — | $39.2K | +157.9% | 17.4% |
Q3 2025 2025-09-30 | $258.3K | +303816.5% | $48.6K | +984.8% | 18.8% |
Q2 2025 2025-06-30 | $112.8K | +641.9% | $30.0K | +391.5% | 26.6% |
Q1 2025 2025-03-31 | $241.1K | — | $37.5K | +343.7% | 15.6% |
Q4 2024 2024-12-31 | — | — | $-67.7K | — | — |
Q3 2024 2024-09-30 | $85 | — | $-5.5K | +45.9% | -6464.7% |
Q2 2024 2024-06-30 | $15.2K | — | $-10.3K | -11.6% | -67.8% |
Q1 2024 2024-03-31 | — | — | $-15.4K | — | — |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Plastic Materials, Synth Resins & Nonvulcan Elastomers · SIC 2821
Your notes
Keep private notes on HGYN — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
No insider transactions on file for HGYN in the last 12 months.
Source: SEC Form 4 filings. Backfill runs nightly.
Who owns HGYN
No institutional holdings on file for HGYN yet.
Source: SEC Form 13F-HR. Updated quarterly (45-day filing lag).
Top questions investors are asking
Coming once HGYN's latest filing finishes processing.